Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 10/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.32 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032190 | 0.88 | KDM4E (0.39) | TXNRD1KDM4EALDH1A1KMT2AGAA | |
| SCHEMBL3885454 | 0.86 | TXNRD1 (0.39) | TXNRD1KDM4EALDH1A1KMT2AGAA | |
| SCHEMBL1028805 | 0.84 | PIN1 (0.34) | KDM4EGAASMN1; SMN2 | |
| SCHEMBL1032439 | 0.83 | SSTR4 (0.33) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1027137 | 0.76 | SSTR4 (0.34) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1030184 | 0.74 | TXNRD1 (0.43) | TXNRD1KDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3899401 | 0.73 | KDM4E (0.42) | TXNRD1KDM4EALDH1A1KMT2AGAA | |
| SCHEMBL26087592 | 0.73 | TXNRD1 (0.46) | TXNRD1ALDH1A1KMT2AGSRSMN1; SMN2 | |
| SCHEMBL12113606 | 0.72 | TXNRD1 (0.51) | TXNRD1ALDH1A1GSRMAPT | |
| SCHEMBL1027194 | 0.72 | KDM4E (0.36) | KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383641-B2 | Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-02-26 | — | — | US | disclosed |
| EP-2013179-B1 | ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-01-19 | — | — | EP | disclosed |
| US-20090143383-A1 | ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143383-A1 | ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | SLC6A3, DRD3, MC3R | TXNRD1 1756/4885KDM4E 2181/4885ALDH1A1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.